Clearside Biomedical, Inc.

NasdaqGM:CLSD Stok Raporu

Piyasa değeri: US$75.5m

Clearside Biomedical Yönetim

Yönetim kriter kontrolleri 2/4

Clearside Biomedical CEO'su George Lasezkay, Apr2019 tarihinde atandı, in görev süresi 5.58 yıldır. in toplam yıllık tazminatı $ 1.54M olup, şirket hissesi ve opsiyonları dahil olmak üzere 35.6% maaş ve 64.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.51% ine doğrudan sahiptir ve bu hisseler $ 386.59K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 5.4 yıldır.

Anahtar bilgiler

George Lasezkay

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi35.6%
CEO görev süresi5.6yrs
CEO sahipliği0.5%
Yönetim ortalama görev süresi2.3yrs
Yönetim Kurulu ortalama görev süresi5.4yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

CEO Tazminat Analizi

George Lasezkay'un ücretlendirmesi Clearside Biomedical'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$33m

Mar 31 2024n/an/a

-US$35m

Dec 31 2023US$2mUS$547k

-US$32m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$36m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$532k

-US$33m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

US$83k

Dec 31 2021US$2mUS$516k

US$376k

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$1mUS$503k

-US$18m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$1mUS$385k

-US$31m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$67m

Mar 31 2019n/an/a

-US$82m

Dec 31 2018US$150kn/a

-US$83m

Sep 30 2018n/an/a

-US$78m

Jun 30 2018n/an/a

-US$72m

Mar 31 2018n/an/a

-US$65m

Dec 31 2017US$167kn/a

-US$59m

Tazminat ve Piyasa: George 'nin toplam tazminatı ($USD 1.54M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 655.02K ).

Tazminat ve Kazançlar: George şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

George Lasezkay (72 yo)

5.6yrs

Görev süresi

US$1,538,627

Tazminat

Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
George Lasezkay
President5.6yrsUS$1.54m0.51%
$ 386.6k
Charles Deignan
Chief Financial Officer12.8yrsUS$854.41k0.45%
$ 340.8k
Jenny Kobin
Head of Investor Relationsno dataVeri yokVeri yok
Rick McElheny
Senior Vice President of Corporate Development & Alliance Management2.2yrsVeri yokVeri yok
Rafael Andino
Senior Vice President of Engineering & Manufacturing1.8yrsVeri yokVeri yok
Susan Coultas
Chief Clinical Officer2.4yrsVeri yokVeri yok
Ngai Hang Chong
Chief Medical Officerless than a yearVeri yok0.085%
$ 64.1k
Leslie Zacks
Secretaryno dataVeri yokVeri yok

2.3yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: CLSD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
George Lasezkay
President7.3yrsUS$1.54m0.51%
$ 386.6k
Christy Shaffer
Independent Director12.8yrsUS$86.08k0.0059%
$ 4.4k
Benjamin Yerxa
Independent Director2.7yrsUS$88.58k0.024%
$ 18.1k
Jeffrey Edwards
Independent Director6.2yrsUS$88.58k0%
$ 0
Clay Thorp
Independent Chair of the Board12.8yrsUS$96.08k0.054%
$ 40.9k
Carl Regillo
Member of Scientific Advisory Board4.6yrsVeri yokVeri yok
William Humphries
Independent Director12.8yrsUS$91.71k0.068%
$ 51.5k
David Boyer
Member of Scientific Advisory Board4.6yrsVeri yokVeri yok
Nancy Hutson
Independent Director4.6yrsUS$85.46k0.12%
$ 93.9k
Richard Croarkin
Independent Director8.8yrsUS$91.08k0%
$ 0
Arshad Khanani
Member of Scientific Advisory Board1.6yrsVeri yokVeri yok
Lejla Vajzovic
Member of Scientific Advisory Board1.6yrsVeri yokVeri yok

5.4yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CLSD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).